An immunotracer, 125Habeled RM2 (125I-RM2) has been reported to be useful for nuclear imaging of prostate cancer. According to both in vitro and in vivo studies, the uptake of 125I-RM2 in the prostate cancer cells, PC-3 and LNCaP, increased 6 hours after incubation with the tracer. This tracer uptake was blocked when the tumor cells were pretreated with unlabelled RM2. In the tumor-bearing mice, the tracer uptake was higher than that of muscle tissue at 72 hours after the tracer injection. 125I-RM2 showed excellent prostate cancer cell targeting, both in vitro and in vivo. Accordingly, RM2 seems to be a candidate for use as a radioimmunotracer ligand for prostate cancer imaging.
|ジャーナル||Nishinihon Journal of Urology|
|出版ステータス||Published - 2010 2|
ASJC Scopus subject areas